Fauna Bio has achieved a significant milestone in its collaboration with Eli Lilly & Company by designating a target for obesity treatment, utilizing insights from its Convergence AI platform. This partnership, initiated in December 2023, aims to explore innovative therapeutic avenues based on the biology of hibernating mammals. The identification of this target not only highlights the potential for a first-in-class obesity treatment but also triggers a financial payment to Fauna Bio as part of their agreement.

The Convergence AI platform stands out by analyzing genomic data from over 450 mammal species, including more than 60 hibernators, to uncover disease-relevant targets. By integrating comparative genomics with human patient data, Fauna Bio is paving the way for novel therapeutic strategies in metabolic diseases. This approach reflects a growing trend in the longevity and healthspan fields, where leveraging unique biological adaptations can lead to groundbreaking treatments.

For professionals in aging biology and metabolic research, this development underscores the potential of cross-species insights in addressing complex health challenges like obesity, reinforcing the importance of innovative methodologies in therapeutic discovery.

Source: longevity.technology